REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/11/2025
Back to search
Official data from USPTO
PROTEOSTASIS THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PROTEOSTASIS THERAPEUTICS
ST13
US500000088363795Class
5
Filing
88363795
Registration
5986569
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
02/11/2025
Trademark type
Word
Nice classes
5
Filing date
03/29/2019
Registration date
02/11/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/11/2020
Last transaction
02/11/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
06/30/2016
First use in commerce
06/30/2016
Drawing code
4
Owner type
03
Owner location
Boston, MA
Examiner
WLODARCZYK, CAROLYN
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Proteostasis Therapeutics, Inc.
Representatives
JOHN L. DUPRE' HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of disorders in the nature of digestive disordersophthalmic disordershepatic disordersrespiratory disorderssweat disorderpancreatic disordersreproductive disordersendocrine disorders; medical diagnostic assays for testing of body fluids; medical diagnostic assays for testing human cells for responses to therapy
Publications
History of USPTO decisions and trademark events.
19 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
02/11/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/03/2020
ALIE
ASSIGNED TO LIE
12/26/2019
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
12/24/2019
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
12/21/2019
IUAA
USE AMENDMENT ACCEPTED
12/21/2019
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
12/21/2019
IUAF
USE AMENDMENT FILED
12/21/2019
EAAU
TEAS AMENDMENT OF USE RECEIVED
12/20/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/20/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/20/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/20/2019
GNRT
NON-FINAL ACTION E-MAILED
06/20/2019
CNRT
NON-FINAL ACTION WRITTEN
06/20/2019
DOCK
ASSIGNED TO EXAMINER
06/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/18/2019
NWAP
NEW APPLICATION ENTERED
04/02/2019
Continuous trademark protection
Get notified about every new filing that threatens PROTEOSTASIS THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.